文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

经皮心肌内室间隔射频消融术治疗药物难治性肥厚型梗阻性心肌病

Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.
PubMed 文献 · JAMA Cardiol · 2022-01-01

本研究为单臂开放标签研究,纳入200例药物难治性肥厚型梗阻性心肌病患者,评估经皮心肌内室间隔射频消融术(PIMSRA)的安全性和中期疗效。30天主要不良临床事件率为10.5%,随访期间室间隔厚度和左室流出道压差均显著下降,96%患者心功能改善至NYHA I或II级。

要点

  • PIMSRA术后30天主要不良临床事件率为10.5%,无出血或卒中发生。
  • 随访时室间隔厚度从24.0 mm降至17.3 mm,左室流出道压差从79.0 mmHg降至14.0 mmHg。
  • 96%患者末次随访时NYHA心功能分级为I或II级。

核心结论

  • PIMSRA可能有效缓解药物难治性HOCM患者的左室流出道梗阻和症状,并发症率可接受。

研究设计与样本

  • 单臂开放标签研究,纳入200例药物难治性HOCM患者,来自西安西京医院,2016年10月至2020年6月。

主要发现

  • 30天主要不良临床事件率为10.5%(n=21),包括2例死亡(1.0%)、7例需微型开胸的 pericardial effusion(3.5%)、12例需心包穿刺的 pericardial effusion(6%)。
  • 随访中位时间19个月,室间隔厚度从24.0(5.1)mm降至17.3(4.4)mm(P < .001),左室流出道压差从79.0(53.0)mmHg降至14.0(24.0)mmHg(P < .001)。
  • 96%患者末次随访时NYHA心功能I或II级。

关键数值与推荐

  • 纳入标准:静息或诱发左室流出道压差≥50 mmHg,NYHA II级或以上,且最大耐受药物治疗无效。

临床怎么用

  • 对于药物难治性HOCM患者,PIMSRA可作为缓解流出道梗阻和症状的介入选择。

局限性

  • 单臂研究,无对照组,需随机临床试验与室间隔减容术比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with hypertrophic obstructive cardiomyopathy (HOCM) and drug-refractory symptoms and outflow gradients have limited nonsurgical treatment options. The feasibility of percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) has been reported previously; however, procedural and medium-term outcomes are unknown. OBJECTIVE: To describe the safety and medium-term outcomes of PIMSRA in a large patient cohort with drug-refractory HOCM. DESIGN, SETTING, AND PARTICIPANTS: This was a single-arm, open-label study of PIMSRA in patients with drug-refractory HOCM. Patients presenting to the Xijing Hospital in Xi'an, China, between October 2016 to June 2020 with hypertrophic cardiomyopathy. Of 1314 patients presenting with HOCM, 244 fulfilled inclusion criteria of severe resting/provoked outflow gradients of 50 mm Hg or higher, and symptoms of New York Heart Association functional class of II or higher refractory to maximum tolerated medications. After discussion among the heart team, 40 patients underwent surgical or alcohol septal reduction therapy and 4 required treatment of significant coronary artery disease. INTERVENTIONS: PIMSRA performed in patients. MAIN OUTCOMES AND MEASURES: The primary outcome was 30-day major adverse clinical events: death, emergency surgery, severe effusion requiring intervention, procedure-related stroke, bleeding, and stroke. Secondary outcomes included 30-day technical success and 90-day improvement in outflow obstruction. RESULTS: The mean (SD) age of 200 patients was 46.9 (14.0) years, and 125 (62.5%) were men. Resting or provoked left ventricular outflow tract gradients were 50 mm Hg or higher. The median (IQR) follow-up for all patients was 19 (6-50) months. Thirty-day major adverse clinical events rate was 10.5% (n = 21): there were 2 in-hospital/30-day deaths (1.0%), 7 patients (3.5%) with pericardial effusion requiring mini-thoracotomy, 12 patients (6%) with pericardial effusion requiring pericardiocentesis, and no bleeding or strokes. Other periprocedural complications included permanent right bundle branch block in 5 patients (2.5%), resuscitated ventricular fibrillation in 2 (1.0%), and septal branch aneurysm in 2 (1.0%). There were no permanent pacemaker implantations. At follow-up, maximum septal thickness was reduced from a mean (SD) of 24.0 (5.1) mm to 17.3 (4.4) mm (P < .001), and left ventricular outflow tract gradient was decreased from a mean (SD) of 79.0 (53.0) mm Hg to 14.0 (24.0) mm Hg (P < .001). Overall, 190 patients (96%) with HOCM were in New York Heart Association functional class I or II at last follow-up. CONCLUSIONS AND RELEVANCE: This study found that PIMSRA in patients with drug-refractory HOCM may be an effective procedure for relief of left ventricular outflow tract obstruction and symptoms with acceptable complication rates. These results are encouraging and support the design of a randomized clinical trial against well-established septal reduction therapies.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Zhou M, Ta S, Hahn RT, et al. Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy. JAMA Cardiol. 2022. PMID: 35353129. doi:10.1001/jamacardio.2022.0259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。